Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Glaucoma: Overview01:25

Glaucoma: Overview

1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nicotinamide Supplementation and Primary Open-Angle Glaucoma in Patients With Ocular Hypertension.

JAMA ophthalmology·2026
Same author

Effect of intraocular pressure control on visual field progression in the HORIZON trial.

Ophthalmology. Glaucoma·2026
Same author

Evaluation of the Deep Reality Viewer for teaching slit-lamp examination of the anterior segment and the optic nerve head.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026
Same author

Comparative Outcomes of Standalone Xen63 Gel Stent and Preserflo Microshunt Implantation: A Multicenter Study.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same author

The Flip Sides of Interventional Glaucoma.

Ophthalmology. Glaucoma·2026
Same author

Structure-Function Correlation of Virtual Reality and Standard Perimetry With Peripapillary RNFL OCT in Glaucoma Patients.

Translational vision science & technology·2026

Related Experiment Video

Updated: May 2, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.7K

Improvement in outflow facility by two novel microinvasive glaucoma surgery implants.

Cassandra L Hays1, Vikas Gulati, Shan Fan

  • 1Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, Nebraska.

Investigative Ophthalmology & Visual Science
|February 20, 2014
PubMed
Summary

A novel Schlemm's canal scaffold significantly improved outflow facility (C) by 74% in human eyes ex vivo. This scaffold demonstrated greater efficacy than two micro-bypasses, suggesting potential for reducing intraocular pressure in glaucoma patients.

Keywords:
Schlemm's canaldrainage deviceglaucoma anterior segmentoutflow facility

More Related Videos

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.0K
Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery
04:36

Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery

Published on: April 14, 2026

261

Related Experiment Videos

Last Updated: May 2, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.7K
Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.0K
Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery
04:36

Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery

Published on: April 14, 2026

261

Area of Science:

  • Ophthalmology
  • Glaucoma Research
  • Biomedical Engineering

Background:

  • Glaucoma is a leading cause of irreversible blindness.
  • Elevated intraocular pressure (IOP) is a primary risk factor for glaucoma progression.
  • Improving aqueous humor outflow is a key therapeutic strategy for IOP reduction.

Purpose of the Study:

  • To evaluate the efficacy of a novel Schlemm's canal scaffold in enhancing outflow facility (C).
  • To compare the performance of the scaffold against two trabecular micro-bypasses in human anterior segments.
  • To assess the impact of these devices on outflow resistance across various perfusion pressures.

Main Methods:

  • Human anterior segments from 12 donor pairs were perfused at varying pressures (10-50 mm Hg).
  • Outflow facility (C) was measured at baseline.
  • A Schlemm's canal scaffold was implanted in one eye, and two micro-bypasses in the contralateral eye.

Main Results:

  • The scaffold increased C by 74% (0.16 ± 0.12 μL/min/mm Hg) compared to baseline.
  • Two micro-bypasses increased C by 34% (0.08 ± 0.12 μL/min/mm Hg).
  • The scaffold significantly improved C at perfusion pressures of 20, 30, 40, and 50 mm Hg, while micro-bypasses showed significant improvement only at 40 mm Hg.

Conclusions:

  • Both the scaffold and micro-bypasses increased outflow facility in ex vivo human eyes.
  • The Schlemm's canal scaffold demonstrated a superior increase in C and effectiveness across a wider range of perfusion pressures.
  • The scaffold's ability to dilate Schlemm's canal suggests it may be a promising therapy for reducing IOP in glaucoma patients.